Tumor expression of Fas ligand (CD95L) and the consequences

Curr Opin Immunol. 1998 Oct;10(5):564-72. doi: 10.1016/s0952-7915(98)80225-2.


Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Fas Ligand Protein
  • Humans
  • Membrane Glycoproteins / analysis
  • Membrane Glycoproteins / physiology*
  • Neoplasms / immunology*
  • Neoplasms / pathology
  • T-Lymphocytes / immunology


  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins